Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

被引：11
|
作者：
Paz-Ares, Luis [1 ,2 ]
机构：
[1] Inst Biomed Sevilla, Seville, Spain
[2] Hosp Univ Virgen del Rocio, Seville, Spain
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 03期
关键词：
CELL LUNG-CANCER; PHASE-III TRIAL; DOCETAXEL; GEFITINIB; EGFR;
D O I：
10.1016/S1470-2045(12)70001-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：225 / 227
页数：4
相关论文
共 50 条
  • [31] Pembrolizumab + axitinib beyond first-line therapy for mRCC
    Tim Thomas
    Nature Reviews Urology, 2023, 20 : 131 - 131
  • [32] Intraarterial chemotherapy as the first-line therapy in penile cancer
    Chiang, P-H
    Chen, C-H
    Shen, Y-C
    BRITISH JOURNAL OF CANCER, 2014, 111 (06) : 1089 - 1094
  • [33] Intraarterial chemotherapy as the first-line therapy in penile cancer
    P-H Chiang
    C-H Chen
    Y-C Shen
    British Journal of Cancer, 2014, 111 : 1089 - 1094
  • [34] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [35] Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers
    Patil, V
    Karpe, A.
    Noronha, V
    Joshi, A.
    Muddu, V
    Bhattacharjee, A.
    Dhumal, S.
    Prabhash, K.
    INDIAN JOURNAL OF CANCER, 2015, 52 (04) : 629 - 631
  • [36] First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC
    Zhou, Caicun
    Solomon, Benjamin
    Loong, Herbert H.
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Han, Baohui
    Zhou, Jianying
    Ardizzoni, Andrea
    Mak, M. Perez
    Santini, Fernando C.
    Elamin, Yasir Y.
    Drilon, Alexander
    Wolf, Juergen
    Payakachat, Nalin
    Uh, Minji K.
    Rajakumar, Deborah
    Han, Hongmei
    Puri, Tarun
    Soldatenkova, Victoria
    Lin, A. Bence
    Lin, Boris K.
    Goto, Koichi
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (20): : 1839 - 1850
  • [37] Clinical characteristics of KRAS mutations in NSCLC and their impact on outcomes to first-line chemotherapy
    Butaney, Mohit
    Porter, Jennifer
    Lindeman, Neal Ian
    Janne, Pasi A.
    Rabin, Michael S.
    Marcoux, J. Paul
    Johnson, Bruce E.
    Jackman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Influence of baseline inflammatory markers on the response to first-line chemotherapy in advanced NSCLC
    MacDonald, N.
    Kasymjanova, G.
    Agulnik, J. S.
    Pepe, C.
    Kreisman, H.
    Cohen, V.
    Sharma, R.
    Gagnon, B.
    Small, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 385 - 385
  • [39] Cimavax-EGF in Combination with First-Line Chemotherapy in III Stage NSCLC
    Neninger, E.
    Caceres, H.
    Camacho, K.
    Hernandez, M.
    Santiesteban, E.
    Del Castillo, C.
    Menendez, Y.
    Gonzalez, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S676 - S677
  • [40] First-line immune-chemotherapy combination for squamous NSCLC is already a reality
    Hendriks, Lizza E. L.
    Menis, Jessica
    Remon, Jordi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 819 - 823
12345